Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 15romidepsin 9Whole-Body Irradiation 9fludarabine phosphate 8Vincristine 8Etoposide 8Doxorubicin 8Prednisone 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Brentuximab Vedotin 610-propargyl-10-deazaaminopterin 6Rituximab 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cyclosporine 5denileukin diftitox 4Nivolumab 4Lenalidomide 4mogamulizumab 3Tacrolimus 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Dexamethasone 3Alemtuzumab 3selinexor 2pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡